| [1] |
Bray F, Ferlay J, Soerjomataram I，et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68(6): 394-424.
|
| [2] |
Omyla-Staszewska J, Deptala A. Effective therapeutic management of hepatocellular carcinoma-on the basis of a clinical case[J]. Contemp Oncol（Pozn），2012，16(1): 60-63.
|
| [3] |
Raoul JL, Kudo M, Finn RS，et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond[J]. Cancer Treat Rev，2018，68: 16-24.
|
| [4] |
Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond[J]. World J Gastroenterol，2019，25(7): 789-807.
|
| [5] |
Sun WJ, Cabrera R. Systemic treatment of patients with advanced，unresectable hepatocellular carcinoma: emergence of therapies[J]. J Gastrointest Cancer，2018，49(2): 107-115.
|
| [6] |
Kudo M, Ueshima K, Torimura T，et al. Randomized，open label，multicenter，phase II trial of transcatheter arterial chemoembolization（TACE）therapy in combination with sorafenib as compared with TACE mechalone in patients with hepatocellular carcinoma: TACTICS trial[J]. JCO，2018，36(15_suppl): 4017.
|
| [7] |
Mody K, Abou-Alfa GK. Systemic therapy for advanced hepatocellular carcinoma in an evolving landscape[J]. Curr Treat Options Oncol，2019，20(2): 3.
|
| [8] |
Gong XL, Qin SK. Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr，2018，7(6): 466-474.
|
| [9] |
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature，2011，473(7347): 298-307.
|
| [10] |
Llovet JM, Villanueva A, Lachenmayer A，et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J]. Nat Rev Clin Oncol，2015，12(8): 436.
|
| [11] |
Johnson PJ, Qin SK, Park JW，et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable，advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study[J]. J Clin Oncol，2013，31(28): 3517-3524.
|
| [12] |
Cheng AL, Kang YK, Lin DY，et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial[J]. J Clin Oncol，2013，31(32): 4067-4075.
|
| [13] |
Cainap C, Qin SK, Huang WT，et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial[J]. J Clin Oncol，2015，33(2): 172-179.
|
| [14] |
Zhu AX, Kudo M, Assenat E，et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial[J]. JAMA，2014，312(1): 57-67.
|
| [15] |
Rimassa L, Assenat E, Peck-Radosavljevic M，et al. Second-line tivantinib（ARQ 197）vs placebo in patients（Pts）with MET-high hepatocellular carcinoma（HCC）: Results of the METIV-HCC phase III trial[J]. JCO，2017，35(15_suppl): 4000.
|
| [16] |
Kudo M, Kang YK, Park JW，et al. Regional differences in efficacy，safety，and biomarkers for second-line axitinib in patients with advanced hepatocellular carcinoma: from a randomized phase II study[J]. Liver Cancer，2018，7(2): 148-164.
|
| [17] |
Wilhelm SM, Carter C, Tang LY，et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res，2004，64(19): 7099-7109.
|
| [18] |
Llovet JM, Ricci S, Mazzaferro V，et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med，2008，359(4): 378-390.
|
| [19] |
Cheng AL, Kang YK, Chen ZD，et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised，double-blind，placebo-controlled trial[J]. Lancet Oncol，2009，10(1): 25-34.
|
| [20] |
Bruix J, Takayama T, Mazzaferro V，et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation（STORM）：a phase 3，randomised，double-blind，placebo-controlled trial[J]. Lancet Oncol，2015，16(13): 1344-1354.
|
| [21] |
Kudo M, Imanaka K, Chida N，et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer，2011，47(14): 2117-2127.
|
| [22] |
Lencioni R, Llovet JM, Han GH，et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial[J]. J Hepatol，2016，64(5): 1090-1098.
|
| [23] |
Meyer T, Fox R, Ma YT，et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma（TACE 2）: a randomised placebo-controlled，double-blind，phase 3 trial[J]. Lancet Gastroenterol Hepatol，2017，2(8): 565-575.
|
| [24] |
Yao Q, Zhang HS, Xiong B，et al. Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study[J]. Oncotarget，2017，8(45): 79012-79022.
|
| [25] |
Tohyama O, Matsui J, Kodama K，et al. Antitumor activity of lenvatinib（e7080）: an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models[J]. J Thyroid Res，2014，2014: 638747.
|
| [26] |
Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date[J]. J Hepatocell Carcinoma，2019，6: 31-39.
|
| [27] |
Ikeda M, Okusaka T, Mitsunaga S，et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res，2016，22(6): 1385-1394.
|
| [28] |
Kudo M, Finn RS, Qin SK，et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet，2018，391(10126): 1163-1173.
|
| [29] |
Kudo M. Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma[J]. Liver Cancer，2018，7(3): 215-224.
|
| [30] |
Kudo M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma[J]. Liver Cancer，2018，7(1): 1-19.
|
| [31] |
Jackson R, Psarelli EE, Berhane S，et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: A meta-analysis of randomized phase III trials[J]. J Clin Oncol，2017，35(6): 622-628.
|
| [32] |
Wilhelm SM, Dumas J, Adnane L，et al. Regorafenib（BAY 73-4506）: a new oral multikinase inhibitor of angiogenic，stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J]. Int J Cancer，2011，129(1): 245-255.
|
| [33] |
Bruix J, Tak WY, Gasbarrini A，et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre，open-label，phase II safety study[J]. Eur J Cancer，2013，49(16): 3412-3419.
|
| [34] |
Bruix J, Qin SK, Merle P，et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment （RESORCE）：a randomised，double-blind，placebo-controlled，phase 3 trial[J]. Lancet，2017，389(10064): 56-66.
|
| [35] |
Bruix J, Merle P, Granito A，et al. Hand-foot skin reaction （HFSR）and overall survival（OS）in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma（HCC）progressing on sorafenib[J]. JCO，2018，36(4_suppl): 412.
|
| [36] |
Finn RS, Merle P, Granito A，et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial[J]. J Hepatol，2018，69(2): 353-358.
|
| [37] |
Kudo M. Regorafenib as second-line systemic therapy may change the treatment strategy and management paradigm for hepatocellular carcinoma[J]. Liver Cancer，2016，5(4): 235-244.
|
| [38] |
Cohn AL, Kelley RK, Yang TS，et al. Activity of cabozantinib （XL184）in hepatocellular carcinoma patients（pts）: Results from a phase II randomized discontinuation trial（RDT）[J]. JCO，2012，30(4_suppl): 261.
|
| [39] |
Abou-Alfa GK, Meyer T, Cheng AL，et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med，2018，379(1): 54-63.
|
| [40] |
Kelley RK, Ryoo BY, Merle P，et al. Outcomes in patients（pts）who had received sorafenib（S）as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib（C）versus placebo （P）in advanced hepatocellular carcinoma（HCC）[J]. JCO，2018，36(15_suppl): 4088.
|
| [41] |
Zhu AX, Park JO, Ryoo BY，et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib（REACH）: a randomised，double-blind，multicentre，phase 3 trial[J]. Lancet Oncol，2015，16(7): 859-870.
|
| [42] |
Zhu AX, Kang YK, Yen CJ，et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations（REACH-2）: a randomised，double-blind，placebo-controlled，phase 3 trial[J]. Lancet Oncol，2019，20(2): 282-296.
|
| [43] |
Kudo M. Ramucirumab as second-line systemic therapy in hepatocellular carcinoma[J]. Liver Cancer，2018，7(4): 305-311.
|
| [44] |
Zhu J, Yin TL, Xu Y，et al. Therapeutics for advanced hepatocellular carcinoma: Recent advances，current dilemma，and future directions[J]. J Cell Physiol，2019-1-15. [Epub ahead of print]
|
| [45] |
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application[J]. Int Immunol，2007，19(7): 813-824.
|
| [46] |
Nivolumab approved for liver cancer[J]. Cancer Discov，2017，7(11): OF3.
|
| [47] |
Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation[J]. J Exp Med，1995，182(2): 459-465.
|
| [48] |
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade[J]. Science，1996，271(5256): 1734-1736.
|
| [49] |
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nat Rev Cancer，2019，19(3): 133-150.
|
| [50] |
Forde PM, Chaft JE, Smith KN，et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med，2018，378(21): 1976-1986.
|
| [51] |
Lu X, Horner JW, Paul E，et al. Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer[J]. Nature，2017，545(7652): 116.
|
| [52] |
Turajlic S, Larkin J. Immunotherapy for melanoma metastatic to the brain[J]. N Engl J Med，2018，379(8): 789-790.
|
| [53] |
Obeid JM, Kunk PR, Zaydfudim VM，et al. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?[J]. Cancer Immunol Immunother，2018，67(2): 161-174.
|
| [54] |
Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update[J]. Liver Cancer，2016，6(1): 1-12.
|
| [55] |
Topalian SL, Hodi FS, Brahmer JR，et al. Safety，activity，and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med，2012，366(26): 2443-2454.
|
| [56] |
El-Khoueiry AB, Sangro B, Yau TC，et al. Phase I/II safety and antitumor activity of nivolumab（nivo）in patients（pts）with advanced hepatocellular carcinoma（HCC）: Interim analysis of the CheckMate-040 dose escalation study[J]. JCO，2016，34(15_suppl): 4012.
|
| [57] |
El-Khoueiry AB, Sangro B, Yau T，et al. Nivolumab in patients with advanced hepatocellular carcinoma（CheckMate 040）: an open-label，non-comparative，phase 1/2 dose escalation and expansion trial[J]. Lancet，2017，389(10088): 2492-2502.
|
| [58] |
Sangro B, Park JW, Dela Cruz CM，et al. A randomized，multicenter，phase 3 study of nivolumab vs sorafenib as first-line treatment in patients（pts）with advanced hepatocellular carcinoma （HCC）: CheckMate-459[J]. JCO，2016，34(15_suppl): TPS4147.
|
| [59] |
Finkelmeier F, Czauderna C, Perkhofer L，et al. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers[J]. J Cancer Res Clin Oncol，2019，145(1): 253-259.
|
| [60] |
Zhu AX, Finn RS, Edeline J，et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib（KEYNOTE-224）: a non-randomised，open-label phase 2 trial[J]. Lancet Oncol，2018，19(7): 940-952.
|
| [61] |
Finn RS, Chan SL, Zhu AX，et al. KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma[J]. JCO，2017，35(4_suppl): TPS503.
|
| [62] |
Gavin MA, Rasmussen JP, Fontenot JD，et al. Foxp3-dependent programme of regulatory T-cell differentiation[J]. Nature，2007，445(7129): 771-775.
|
| [63] |
Wu YQ, Borde M, Heissmeyer V，et al. FOXP3 controls regulatory T cell function through cooperation with NFAT[J]. Cell，2006，126(2): 375-387.
|
| [64] |
Sangro B, Gomez-Martin C, de la Mata M，et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol，2013，59(1): 81-88.
|
| [65] |
Duffy AG, Ulahannan SV, Makorova-Rusher O，et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol，2017，66(3): 545-551.
|
| [66] |
Melero I, Hervas-Stubbs S, Glennie M，et al. Immunostimulatory monoclonal antibodies for cancer therapy[J]. Nat Rev Cancer，2007，7(2): 95-106.
|
| [67] |
Berger R, Rotem-Yehudar R, Slama G，et al. Phase I safety and pharmacokinetic study of CT-011，a humanized antibody interacting with PD-1，in patients with advanced hematologic malignancies[J]. Clin Cancer Res，2008，14(10): 3044-3051.
|
| [68] |
Motzer RJ, Penkov K, Haanen J，et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med，2019，380(12): 1103-1115.
|
| [69] |
Choueiri TK, Larkin J, Oya M，et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma（JAVELIN Renal 100）: an open-label，dose-finding and dose-expansion，phase 1b trial[J]. Lancet Oncol，2018，19(4): 451-460.
|
| [70] |
McDermott DF, Huseni MA, Atkins MB，et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma[J]. Nat Med，2018，24(6): 749-757.
|
| [71] |
Wallin JJ, Bendell JC, Funke R，et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma[J]. Nat Commun，2016，7: 12624.
|
| [72] |
Lee KH, Hsu CH, Lee MS，et al. Atezolizumab plus bevacizumab in hepatocellular carcinoma（HCC）: Safety and clinical activity results from a phase Ib study[J]. Ann Oncol，2018，29: 47.
|
| [73] |
Pishvaian MJ, Lee MS, Ryoo BY，et al. LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma（HCC）[J]. Ann Oncol，2018，29(suppl_8): 2.
|
| [74] |
Kelley RK, Abou-Alfa GK, Bendell JC，et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma（HCC）: Phase I safety and efficacy analyses[J]. JCO，2017，35(15_suppl): 4073.
|
| [75] |
Dawkins J, Webster RM. The hepatocellular carcinoma market[J]. Nat Rev Drug Discov，2019，18(1): 13-14.
|
| [76] |
Taylor M, Dutcus CE, Schmidt E，et al. A phase 1b trial of lenvatinib（LEN）plus pembrolizumab（PEM）in patients with selected solid tumors[J]. Ann Oncol，2016，27(suppl_6): 1.
|
| [77] |
Ikeda M, Sung MW, Kudo M，et al. A phase 1b trial of lenvatinib （LEN）plus pembrolizumab（PEM）in patients（pts）with unresectable hepatocellular carcinoma（uHCC）[J]. JCO，2018，36(15_suppl): 4076.
|
| [78] |
Xu JM, Zhang Y, Jia R，et al. Anti-programmed death-1 antibody SHR-1210（S）combined with apatinib（A）for advanced hepatocellular carcinoma（HCC），gastric cancer（GC）or esophagogastric junction（EGJ）cancer refractory to standard therapy: A phase 1 trial[J]. JCO，2018，36(15_suppl): 4075.
|
| [79] |
Kudo M. Combination cancer immunotherapy with molecular targeted agents/anti-CTLA-4 antibody for hepatocellular carcinoma[J]. Liver Cancer，2019，8(1): 1-11.
|